Feed HRMY
HR

Harmony Biosciences Holdings, Inc.

HRMY · NASDAQ

$42.02 -1.29% (-$0.55)
1M +10.14%
Market Cap $2.47B
P/E Ratio 13.65x
Div. Yield -
ROE 20.06%

Bulios Fair Price

$56.11

33.5% upside

Preț actual

$42.02

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile HRMY sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Moderate
5/9
Valuation
87 /100
Cheap
P/E 13.65x
EV/EBITDA 7.52x
P/S 2.58x
Growth
74 /100
Growing
EPS growth 3.01%
Rev. growth 25.64%
FCF growth 34.09%
Profitability
99 /100
Strong
Gross margin 75.42%
Net margin 18.88%
Op. margin 24.03%
Quality
83 /100
Excellent
ROIC 14.96%
ROE 20.06%
ROA 13.20%
Debt
100 /100
Low
Debt/Equity 0.15x
Current ratio 3.48x
Int. coverage 18.62x
Stability
90 /100
Stable
Beta 0.93x
Rev. volatility 6.25%
EPS volatility 24.29%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre HRMY
Online

Despre companie

Harmony Biosciences Holdings, Inc. (HRMY) is an American company specializing in research, development, and commercialization of drugs and therapies for sleep disorders and neurological conditions. With activities in biotechnology and pharmaceuticals, Harmony Biosciences Holdings is a key player in the world of sleep disorder and neurological condition treatment. Their research focuses on innovative treatment approaches and therapies for various sleep disorders, such as narcolepsy. The company aims to improve the lives of patients suffering from these conditions and provide modern treatment solutions. Harmony Biosciences Holdings is characterized by expertise in neurology and the treatment of sleep disorders. Harmony Biosciences Holdings, Inc. (HRMY) shares could be suitable for investors looking for an investment opportunity in the biotechnology and pharmaceutical sector with a company focused on innovations in the treatment of sleep disorders and neurological conditions and enhancing the quality of life for patients.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Jeffrey Dayno

Employees

293

Headquarters

Plymouth Meeting

Evenimente viitoare

03 NOV.

Earnings

Upcoming earnings report

44d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.